GRAIL PATHFINDER 2 Results Show Galleri ® Multi-Cancer Early Detection Blood Test Increased Cancer Detection More Than Seven-Fold When Added to USPSTF A and B Recommended Screenings
Saturday, October 18, 2025 1 min read
Key Takeaway: GRAIL, Inc. announced positive results from its PATHFINDER 2 study, showcasing the Galleri multi-cancer early detection blood test. The study revealed a more than seven-fold increase in cancer detection when combined with recommended screenings. Notably, over half of the cancers detected were early-stage, and a significant portion lacked existing screening recommendations.
Market Sentiment Analysis
POSITIVE FACTORS
Galleri test significantly increased cancer detection rates.
More than half of detected cancers were in early stages.
Three-quarters of cancers identified had no recommended screenings.
Full Press Release Details
More Than Half of Cancers Detected by Galleri Were Early Stage
Approximately Three-Quarters of Galleri-Detected Cancers Do Not Have Recommended Screenings
PATHFINDER 2 is the Largest U.S. Multi-Cancer Early Detection (MCED) Interventional Study in the Cancer Screening Population
MENLO PARK, Calif.,Oct. 17, 2025/PRNewswire/ -- GRAIL, Inc. (Nasdaq:GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that positive performance and safety results from its registrational PATHFINDER 2 study are being presented at the European Society for Medical Oncology (ESMO) Congress 20251.
Frequently Asked Questions
What is the Galleri test?
The Galleri test is a multi-cancer early detection blood test developed by GRAIL.
What were the results of the PATHFINDER 2 study?
The study showed a more than seven-fold increase in cancer detection rates.
How many cancers detected were early stage?
More than half of the cancers detected by Galleri were classified as early stage.
What percentage of detected cancers lacked recommended screenings?
Approximately three-quarters of the cancers detected did not have recommended screenings.